$INSM

Adsett Roger sold $32.0M of INSM

Adsett Roger (Chief Operating Officer) sold 239,850 shares of INSMED Inc (INSM) at $133.27 ($31.96M total) on 2026-08-10.

Original reporting
SEC EDGAR · Adsett Roger
Published Aug 12, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The newest information is the disclosed sale size, price, and post-transaction holdings; it may influence short-term sentiment but does not introduce new operating or financial fundamentals.

02

Market read

Traders may monitor for follow-on insider activity or any concurrent company disclosures, but this filing alone is unlikely to drive a major repricing.

03

What to watch

The filing lacks context on tax, diversification, or planned selling cadence, so traders should avoid extrapolating to company fundamentals from one transaction.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

This is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED COO Adsett Roger sold 239,850 shares in an open-market transaction valued at about $31.96M, per a new Form 4 filing.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source Form 4 disclosure with transaction size and price, but it provides no accompanying company-specific news, guidance change, or 10b5-1 plan details.

Market effects

No sector read-through is provided beyond a single insider sale in a biotech issuer.

None indicated.

None indicated.

Counterpoint

Insider sales are often routine for diversification or liquidity needs, and the absence of a stated 10b5-1 plan does not automatically imply negative information.

Key entities

  • INSMED Inc

    Company whose insider transaction is disclosed on Form 4.

  • Adsett Roger

    Chief Operating Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMMedAI 8/10

Insmed (INSM) Q2 2026 Earnings Call Transcript

Insmed (INSM) reported Q2 2026 revenues of $425.5M, including $309.2M from BRINSUPRI. BRINSUPRI revenue grew 49% sequentially, and ARIKAYCE revenue rose 8% YoY to $116.3M. 2026 BRINSUPRI guidance was raised to $1.25B-$1.4B, and cash was $1.2B at June 30. Net loss was $13.2M.

$INSMMed

Insmed Q2 Earnings Call Highlights

Insmed (INSM) reported Q2 call highlights. It narrowed BRINSUPRI gross-to-net guidance to mid-to-high 20% and raised global peak sales to over $7B. It expects ARIKAYCE expansion filings in the U.S. and Japan, with Japan application in 2H26. TPIP peak sales estimate rose to over $6B. Cash was about $1.2B; it targets cash-flow positivity in 2027.